Venlafaxine Hydrochloride
Product Images NDC 53217-194

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 53217-194). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (Venlafaxine HCl Er Cadila 1)

Venlafaxine Hydrochloride Extended-release Capsules, Usp (Venlafaxine HCl Er  Cadila 1)
This text seems to be a documentation of drug interactions and their effects on the PK (pharmacokinetics) of different analytes. The interacting drugs mentioned include Ethanol, Diazepam, Cimetidine, Ketoconazole, Indinavir, Metoprolol, Imipramine, and Lithium. The effects of these drugs on CYP2D6 EM's and PM's are highlighted. The analyte mentioned in the text is Venlafaxine. There are recommendations for the use of these drugs in patients - some require dose adjustments, while others need to be avoided or used with caution, especially in patients with hypertension, elderly, or hepatic dysfunction. The text mentions PK Fold Change and 90% C recommendation, but it's not clear what they refer to.*
FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (Venlafaxine HCl Er Cadila 2)

Venlafaxine Hydrochloride Extended-release Capsules, Usp (Venlafaxine HCl Er  Cadila 2)
This document appears to be a chart of different drugs and their interactions. The first column lists a variety of drugs, while the second column includes some type of code or identifier. The remaining columns list various parameters for each drug including their PKFold change and recommended dosage adjustments. The end of the document includes a section on changes relative to a reference value, but it is not clear what this is referring to.*
FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (Venlafaxine HCl Er Cadila 3)

Venlafaxine Hydrochloride Extended-release Capsules, Usp (Venlafaxine HCl Er  Cadila 3)
This text appears to be a chart or table providing information on recommended dose adjustments for the drug venlafaxine based on various factors such as age, kidney and liver function, and genetic factors. The table recommends reducing the dose of venlafaxine by various percentages depending on these factors, and suggests individualized dosing may be necessary in some cases. There are also measurements of Cmax and AuC, as well as information on fold change and 90% CI.*
FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (Venlafaxine HCl Er Cadila 4)

FDA Label Image

Image Label (Venlafaxine HCl Er Cadila 5)

Image Label (Venlafaxine HCl Er  Cadila 5)
This is a description of Venlafaxine HCL ER, USP, a medication with a National Drug Code (NDC) of 53217-0194-60 and 60 capsules per package. Each capsule contains 150mg of active ingredients which are Venlafaxine Hydrochloride, USP and Venlafaxine Hel ER, USP (equivalent to Venlafaxine 150mg). The capsules are white and dark orange oblong-shaped with ZA-37 150mg imprinted on one side, and are the generic version of Effexor XR. It is manufactured by Cadila Healthcare Limited in India and distributed by Pharmaceuticals. This description provides dosage instructions in Spanish and a chart log for the patient's use.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.